June 21, 2021 07:05 AM EDT R&D Jason Mast Editor Eight months after their $88 million IPO, Tarsus Pharmaceuticals say they’ve cleared the first of two trials needed to prove to their FDA that their repurposed dog drug can successfully banish mites from patients’ eyes. The California biotech announced Monday that, in Phase II/III study,...